Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

NCT ID: NCT04642079

Last Updated: 2024-01-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

839 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-04

Study Completion Date

2022-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: =>15 through 23 months of age

20vPnC

Group Type EXPERIMENTAL

20vPnC

Intervention Type BIOLOGICAL

20-valent pneumococcal conjugate vaccine

Cohort 2: 2 through 4 years of age

20vPnC

Group Type EXPERIMENTAL

20vPnC

Intervention Type BIOLOGICAL

20-valent pneumococcal conjugate vaccine

Cohort 3: 5 through 9 years of age

20vPnC

Group Type EXPERIMENTAL

20vPnC

Intervention Type BIOLOGICAL

20-valent pneumococcal conjugate vaccine

Cohort 4: 10 through 17 years of age

20vPnC

Group Type EXPERIMENTAL

20vPnC

Intervention Type BIOLOGICAL

20-valent pneumococcal conjugate vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

20vPnC

20-valent pneumococcal conjugate vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female children ≥15 months to \<18 years of age at the time of consent.
* Healthy children determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.
* For children \<5 years of age, written documentation of receipt of at least 3 doses of 13vPnC. The last dose of 13vPnC must have been administered \>2 months before enrolment into the study

Exclusion Criteria

* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
* Major known congenital malformation or serious chronic disorder
* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results
* Previous vaccination with any investigational pneumococcal vaccine or with PPSV23, or planned receipt through study participation
* Cohorts 3 and 4: Pregnant or breastfeeding female participants
Minimum Eligible Age

15 Months

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northwest Arkansas Pediatrics

Fayetteville, Arkansas, United States

Site Status

The Children's Clinic of Jonesboro, P.A.

Jonesboro, Arkansas, United States

Site Status

The Children's Clinic

Jonesboro, Arkansas, United States

Site Status

California Research Foundation

San Diego, California, United States

Site Status

Pharmax Research Clinic, Inc.

Miami, Florida, United States

Site Status

Bio-Medical Research, LLC

Miami, Florida, United States

Site Status

Children's Health Center

Tampa, Florida, United States

Site Status

Tekton Research, Inc

Chamblee, Georgia, United States

Site Status

Clinical Research Prime

Idaho Falls, Idaho, United States

Site Status

Meridian Clinical Research, LLC

Sioux City, Iowa, United States

Site Status

Alliance for Multispecialty Research, LLC

Newton, Kansas, United States

Site Status

Kentucky Pediatric/ Adult Research

Bardstown, Kentucky, United States

Site Status

Michael W. Simon, M.D., PSC

Lexington, Kentucky, United States

Site Status

MedPharmics, LLC

Gulfport, Mississippi, United States

Site Status

Velocity Clinical Research, Grand Island

Grand Island, Nebraska, United States

Site Status

Midwest Children's Health Research Institute

Lincoln, Nebraska, United States

Site Status

Midwest Children's Health Research Institute

Lincoln, Nebraska, United States

Site Status

Velocity Clinical Research, Norfolk

Norfolk, Nebraska, United States

Site Status

Meridian Clinical Research, LLC

Omaha, Nebraska, United States

Site Status

Velocity Clinical Research, Sioux City

Omaha, Nebraska, United States

Site Status

Wr-Crcn, Llc

Henderson, Nevada, United States

Site Status

MedPharmic's, LLC

Albuquerque, New Mexico, United States

Site Status

Meridian Clinical Research, LLC

Binghamton, New York, United States

Site Status

Dayton Clinical Research

Dayton, Ohio, United States

Site Status

Ohio Pediatric Research Association Inc.

Dayton, Ohio, United States

Site Status

PriMed Clinical Research

Dayton, Ohio, United States

Site Status

Allegheny Health and Wellness Pavilion

Erie, Pennsylvania, United States

Site Status

Lockman & Lubell Pediatric Associates

Fort Washington, Pennsylvania, United States

Site Status

Palmetto Pediatrics, PA

North Charleston, South Carolina, United States

Site Status

Benchmark Research

Austin, Texas, United States

Site Status

University of Texas Medical Branch

Galveston, Texas, United States

Site Status

Tekton Research, Inc

San Antonio, Texas, United States

Site Status

Alliance for Multispecialty Research, LLC

Layton, Utah, United States

Site Status

Wasatch Pediatrics, Cottonwood Office

Murray, Utah, United States

Site Status

Pediatric Care

Provo, Utah, United States

Site Status

JBR Clinical Research

Salt Lake City, Utah, United States

Site Status

J. Lewis Research, Inc. / Foothill Family Clinic

Salt Lake City, Utah, United States

Site Status

J. Lewis Research, Inc./ Foothill Family Clinic South

Salt Lake City, Utah, United States

Site Status

CopperView Medical Center

South Jordan, Utah, United States

Site Status

J. Lewis Research, Inc. / Jordan River Family Medicine

South Jordan, Utah, United States

Site Status

Wee Care Pediatrics

Syracuse, Utah, United States

Site Status

Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice)

Charlottesville, Virginia, United States

Site Status

Pediatric Research of Charlottesville, LLC

Charlottesville, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=B7471014

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B7471014

Identifier Type: -

Identifier Source: org_study_id

2019-003308-11

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.